The global revenue from the systemic sclerosis treatment market stands at US$ 928.1 Million in 2022, with the global market expected to grow at a CAGR of 7.9% to reach a valuation of US$ 2.2 Billion by the end of 2033. According to a recent study by Future Market Insights, drug therapy are leading the market with a share of about 95.4% in the year 2022, within the global market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Size (2023) | US$ 1.0 Billion |
| Projected Market Value (2033) | US$ 2.2 Billion |
| Global Market Growth Rate (2023 to 2033) | 7.9% CAGR |
| Market Share of Top 5 Countries | 67.4% |
| Key Players | fizer Inc.; Sanofi S.A; Cipla Ltd; Accord Healthcare Inc.; Organon LLC; Zydus Lifescience Ltd.; Teva Pharmaceutical Industries Ltd.; Novartis AG; Boehringer Ingelheim Pharmaceuticals, Inc; Amgen Inc; F. Hoffmann-La Roche Ltd; Bayer Healthcare LLC; Johnson & Johnson Services Inc.; Lupin Ltd; GlaxoSmithKline Plc; Medtronic Plc |
Systemic sclerosis, also known as scleroderma, is a chronic autoimmune disease characterized by fibrosis and vascular abnormalities. The prevalence of systemic sclerosis is increasing globally, driving the demand for effective treatment options. As awareness and diagnosis of the disease improve, the market for systemic sclerosis treatments is expected to expand. The introduction of these emerging therapies expands the market and offers hope for improved disease management.
The systemic sclerosis treatment market is expanding in emerging economies due to improving healthcare infrastructure, rising healthcare expenditure, and increased access to specialized care. This expansion presents growth opportunities for systemic sclerosis treatment providers and pharmaceutical companies.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global market recorded a historic CAGR of 7.4% in the last 4 years from 2018 to 2022. Global market systemic sclerosis treatment is around 1.4% of the US$ 68.1 billion global autoimmune disease therapeutics market in 2022, in terms of value share.
Scleroderma, a rare connective tissue disease, affects multiple organs including joints, muscles, skin, and organs. Despite its chronic nature, effective treatment and management strategies enable individuals with scleroderma to lead fulfilling and productive lives, creating opportunities for comprehensive healthcare solutions within this niche market.
The diagnosis of sclerosis can be challenging due to the variability of symptoms and the potential for overlapping with other conditions. Nevertheless, advancements in medical technology and diagnostic techniques have greatly enhanced the accuracy of diagnosis. Magnetic resonance imaging (MRI) is widely utilized to identify and visualize the distinct.
Lesions in the brain and spinal cord that are associated with sclerosis. These advancements have significantly contributed to improving the diagnostic process for sclerosis.
The increasing prevalence of systemic scleroderma worldwide can be attributed to a variety of factors, including genetics, environmental factors, immune system dysfunction, and other factors.
The severity and progression of systemic sclerosis vary among individuals. Patients with more severe symptoms, organ involvement, or rapid disease progression require more intensive treatment regimens. The demand for systemic sclerosis treatment is higher among patients with advanced stages of the disease or those experiencing significant symptoms and complications.
The range of available treatment options plays a significant role in determining demand. Patients and healthcare professionals seek diverse therapeutic choices to address the complex nature of systemic sclerosis. The availability of disease-modifying therapies, immunosuppressants, vasodilators, and supportive care interventions influences the demand for systemic sclerosis treatment.
It has been observed that genetic factors may contribute to the vulnerability of individuals towards autoimmune diseases. There exists a correlation between specific genes and an elevated likelihood of systemic scleroderma. With the advancement of genetic studies, a greater number of individuals with a genetic predisposition may be identified, which could potentially lead to an increase in prevalence rates.
Hence, the global systemic scleroderma treatment market is being driven by the high prevalence and incidence rate of the disease worldwide.
Principal Consultant
A standardized framework is necessary for the assessment of therapeutics for systemic scleroderma, which must be adhered to during the evaluation of the disease.
Economic conditions, such as recessions or economic downturns, can influence the demand for systemic sclerosis treatment. Financial constraints and reduced healthcare budgets may affect patients' ability to access and afford treatments, potentially impacting market growth. The availability and extent of reimbursement and insurance coverage for systemic sclerosis treatments can influence demand. If certain treatments are not adequately covered or reimbursed by insurance providers, it may limit patient access and impact the growth of the treatment market.
Regulatory policies, including drug approval processes, pricing regulations, and intellectual property rights, can impact the growth of systemic sclerosis treatment. Delays in regulatory approvals or changes in pricing regulations may affect the availability and affordability of treatments, potentially impacting market growth.
However, research funding and collaboration among academic institutions, pharmaceutical companies, and government organizations play a crucial role in advancing systemic sclerosis treatment options. Adequate funding and collaborative research efforts can lead to the development of innovative therapies, driving market growth.
With an overall CAGR of 8.4%, the United States has contributed for around 47.2% to the North American market share in 2022.
The trend towards customized medical care and targeted therapeutics is having an effect on the management of systemic sclerosis. While the organization based in USA, are focusing on tailored treatment approaches based on individual patient characteristics, disease subtype, and organ involvement can be developed with an improved understanding of the disease's heterogeneity.
There is potential for more effective and personalized treatment strategies through the development of targeted therapies that address specific mechanisms or pathways implicated in systemic sclerosis.
Japan has contributed for around 5.6% to the global market share in 2022.
Japan's regulatory pathways have been optimized to facilitate the approval and market entry of treatments for systemic sclerosis, resulting in a faster process. The Japanese government's provision of incentives to promote research and development in rare diseases, such as systemic sclerosis, is encouraging innovation and investment in the market.
The provision of unambiguous directives by regulatory agencies regarding clinical trial design, endpoints, and data requisites has been instrumental in streamlining the process of developing and accessing treatments for systemic sclerosis.
The healthcare system in Japan provides adequate reimbursement for treatments related to systemic sclerosis, which serves as a driving force for market expansion and facilitates the availability of cutting-edge therapies.
China held a market share of about 5.3% within the global market in 2022.
The aim of this collaboration was to enhance research and development activities for the production of top-notch generic and complex generic medicines. Which will ultimately reduce the cost of the medicines required for the treatment.
Recent developments in medical research and development in China have included the exploration of autoimmune diseases such as systemic sclerosis. The conducted research has resulted in the emergence of novel treatment alternatives and therapeutic approaches, thereby expanding the scope of possibilities for patients to cope with their medical condition efficiently.
Based on current research trends, it is anticipated that there will be a rise in demand for treatments related to systemic sclerosis.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The drug therapy segment held around 95.4% share of the global market in 2022.
Immunosuppressants function by either hindering the function of specific immune cells or reducing the production of immune system components. The aforementioned medications have the potential to mitigate symptoms, decelerate the advancement of the disease, and impede additional harm to bodily organs. It is common practice to utilize them in conjunction with other treatments, such as corticosteroids, to effectively address the symptoms and potential complications associated with systemic scleroderma.
Immunosuppressants can be a highly effective treatment option so, it is a dominant segment in the therapeutic category.
The limited cutaneous systemic sclerosis segment held around 68.2% share of the total market in 2022.
Genetic factors, environmental triggers, and variations in immune response may play a role in the development of different subtypes of systemic sclerosis.
It's important to note that while limited cutaneous systemic sclerosis may have a higher incidence among the scleroderma types, limited cutaneous systemic sclerosis can cause significant morbidity and can affect various organ systems.
The skin fibrosis segment had around 26.1% of the global market in 2022. The global systemic sclerosis market is worth US$ 242.1 million in total.
Skin involvement is a prominent characteristic of systemic sclerosis and is observed in nearly all patients with systemic sclerosis, with varying degrees and severity.
The injectable segment has contributed for around 47.7% of the global market share in 2022.
For systemic sclerosis treatment, certain medications like immunosuppressants or disease-modifying antirheumatic drugs (DMARDs) may have better efficacy when administered through intravenous or subcutaneous routes.
The rapid and targeted delivery of medication can enhance its therapeutic effects. It indicates that injectable medications have the potential to provide a more direct and efficient delivery of drugs into the bloodstream, as they bypass the digestive system.
This can help to prevent any degradation or alteration of the drug that may occur during oral administration. This particular route of administration may offer increased bioavailability and more consistent drug levels within the body. Which makes it a better option to have than any other route of administration.
The hospital pharmacies a share of about 41.4% in 2022, within the global market in 2022.
Hospitals pharmacies have robust systems in place which can substantially reduce the medication error, like the verification of the dosages and how to use it which helps reduce the risk of the accidents like over dosages and ensure patient safety.
The market for systemic sclerosis treatment has a fair amount of competition. The key players in the market are also putting a lot of effort into expanding their presence in emerging markets with new partnerships and merger acquisitions also focusing on launching new technologically advanced products. The competitive environment includes an analysis of a few global and local businesses that control the market shares. Along with acquisitions and mergers and partnerships with key market players.
Some key instances of development include:
Similarly, the team at Future Market Insights has tracked recent developments related to companies in the systemic sclerosis treatment market, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East and Africa. |
| Key Countries Covered | USA, Canada, Brazil, Argentina, Mexico, Germany, France, UK, Italy, Spain, Russia, BENELUX, Nordic, , India, Thailand, Malaysia, Indonesia, China, Japan, South Korea, Australia, New Zealand, Türkiye, GCC Countries, North Africa, and South Africa |
| Key Market Segments Covered | Therapeutics, Indication, Target Organ, Route of Administration, Distribution Channel and Region |
| Key Companies Covered | Medtronic Plc; GlaxoSmithKline Plc; Lupin Ltd; Johnson & Johnson Services Inc.; Bayer Healthcare LLC; F. Hoffmann-La Roche Ltd; Amgen Inc; Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd.; Zydus Lifescience Ltd.; Organon LLC; Accord Healthcare Inc.; Pfizer, Inc.; Sanofi S.A.; Cipla Ltd. |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The systemic sclerosis treatment market size is US$ 2.2 billion in 2023.
The systemic sclerosis treatment market is anticipated to showcase a 7.9% CAGR between 2023 and 2033.
Treatments for systemic sclerosis encompass drug therapy, primarily immunosuppressants, and hematopoietic stem cell transplantation.
The United States commands the market due to its robust 8.4% CAGR, driven by advanced research and increasing patient awareness.
The aging population, rising awareness, and improved healthcare infrastructure contribute to the increased demand.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Value Added Insights
4.1. Disease Epidemiology
4.2. Pipeline Assessment
4.3. Regulatory Landscape
4.4. Reimbursement Outlook
4.5. Treatment Adoption Analysis
4.6. PESTLE Analysis
4.7. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global Market Outlook
5.1.2. Global Rise in Healthcare Spending
5.2. Forecast Factors - Relevance & Impact
5.2.1. Technological Advancements
5.2.2. Regulatory Framework
5.2.3. Strategic Mergers and Acquisitions by Manufacturers
5.2.4. Increasing Demand for Generic Products
5.2.5. Cross-licensing to broaden the service offerings
5.2.6. Unmet Need for Treatments of Multiple Sclerosis
5.2.7. Frequency of Product Approvals
5.2.8. Growing Product Pipeline
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand (in Value or Size in US$ Million) Analysis 2018 to 2022 and Forecast, 2023 to 2033
6.1. Historical Market Value (US$ Million) Analysis, 2018 to 2022
6.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
6.3. Revenue Opportunity Scenario- Likely/Conservative/Optimistic
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapeutics
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Million) Analysis By Therapeutics, 2018 to 2022
7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Therapeutics, 2023 to 2033
7.3.1. By Drugs Therapy
7.3.1.1. Corticosteroids
7.3.1.2. Immunosuppressant
7.3.1.3. Nonsteroidal Anti-inflammatory Drugs
7.3.1.4. Blood Pressure Medication
7.3.1.5. Proton Pump Inhibitors
7.3.1.6. TNF Inhibitors
7.3.1.7. Light Therapy
7.3.1.8. Nitroglycerin Ointment
7.3.1.9. Others
7.3.2. Hematopoietic Stem Cell Transplantation (HSCT)
7.4. Market Attractiveness Analysis By Therapeutics
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis By Indication, 2018 to 2022
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033
8.3.1. Limited Cutaneous Systemic Sclerosis
8.3.2. Diffuse Cutaneous Systemic Sclerosis
8.4. Market Attractiveness Analysis By Indication
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Target Organ
9.1. Introduction
9.2. Historical Market Size (US$ Million) Analysis By Target Organ, 2018 to 2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Target Organ, 2023 to 2033
9.3.1. Skin Fibrosis
9.3.2. Musculoskeletal
9.3.3. Digital Ulcers
9.3.4. Pulmonary Arterial Hypertension
9.3.5. Gastrointestinal
9.3.6. Pulmonary Fibrosis
9.3.7. Scleroderma Renal Crisis
9.4. Market Attractiveness Analysis By Target Organ
10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
10.1. Introduction
10.2. Historical Market Size (US$ Million) Analysis By Route of Administration, 2018 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
10.3.1. Injectable
10.3.2. Oral
10.3.3. Topical
10.4. Market Attractiveness Analysis By Route of Administration
11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
11.1. Introduction
11.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2018 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
11.3.1. Hospital Pharmacies
11.3.2. Specialty Clinics
11.3.3. Retail Pharmacies
11.3.4. Online Pharmacies
11.4. Market Attractiveness Analysis By Distribution Channel
12. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
12.1. Introduction
12.2. Historical Market Size (US$ Million) Analysis By Region, 2018 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America Analysis 2018 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. USA
13.3.1.2. Canada
13.3.2. By Therapeutics
13.3.3. By Indication
13.3.4. By Target Organ
13.3.5. By Route of Administration
13.3.6. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Therapeutics
13.4.3. By Indication
13.4.4. By Target Organ
13.4.5. By Route of Administration
13.4.6. By Distribution Channel
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. USA Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Therapeutics
13.8.1.2.2. By Indication
13.8.1.2.3. By Target Organ
13.8.1.2.4. By Route of Administration
13.8.1.2.5. By Distribution Channel
13.8.2. Canada Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Therapeutics
13.8.2.2.2. By Indication
13.8.2.2.3. By Target Organ
13.8.2.2.4. By Route of Administration
13.8.2.2.5. By Distribution Channel
14. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. Mexico
14.3.1.2. Brazil
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Therapeutics
14.3.3. By Indication
14.3.4. By Target Organ
14.3.5. By Route of Administration
14.3.6. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Therapeutics
14.4.3. By Indication
14.4.4. By Target Organ
14.4.5. By Route of Administration
14.4.6. By Distribution Channel
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Mexico Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Therapeutics
14.8.1.2.2. By Indication
14.8.1.2.3. By Target Organ
14.8.1.2.4. By Route of Administration
14.8.1.2.5. By Distribution Channel
14.8.2. Brazil Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Therapeutics
14.8.2.2.2. By Indication
14.8.2.2.3. By Target Organ
14.8.2.2.4. By Route of Administration
14.8.2.2.5. By Distribution Channel
14.8.3. Argentina Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Therapeutics
14.8.3.2.2. By Indication
14.8.3.2.3. By Target Organ
14.8.3.2.4. By Route of Administration
14.8.3.2.5. By Distribution Channel
15. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. UK
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Russia
15.3.1.8. Nordic
15.3.1.9. Rest of Europe
15.3.2. By Therapeutics
15.3.3. By Indication
15.3.4. By Target Organ
15.3.5. By Route of Administration
15.3.6. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Therapeutics
15.4.3. By Indication
15.4.4. By Target Organ
15.4.5. By Route of Administration
15.4.6. By Distribution Channel
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. Germany Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Therapeutics
15.8.1.2.2. By Indication
15.8.1.2.3. By Target Organ
15.8.1.2.4. By Route of Administration
15.8.1.2.5. By Distribution Channel
15.8.2. Italy Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Therapeutics
15.8.2.2.2. By Indication
15.8.2.2.3. By Target Organ
15.8.2.2.4. By Route of Administration
15.8.2.2.5. By Distribution Channel
15.8.3. France Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Therapeutics
15.8.3.2.2. By Indication
15.8.3.2.3. By Target Organ
15.8.3.2.4. By Route of Administration
15.8.3.2.5. By Distribution Channel
15.8.4. UK Market Analysis
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Therapeutics
15.8.4.2.2. By Indication
15.8.4.2.3. By Target Organ
15.8.4.2.4. By Route of Administration
15.8.4.2.5. By Distribution Channel
15.8.5. Spain Market Analysis
15.8.5.1. Introduction
15.8.5.2. Market Analysis and Forecast by Market Taxonomy
15.8.5.2.1. By Therapeutics
15.8.5.2.2. By Indication
15.8.5.2.3. By Target Organ
15.8.5.2.4. By Route of Administration
15.8.5.2.5. By Distribution Channel
15.8.6. BENELUX Market Analysis
15.8.6.1. Introduction
15.8.6.2. Market Analysis and Forecast by Market Taxonomy
15.8.6.2.1. By Therapeutics
15.8.6.2.2. By Indication
15.8.6.2.3. By Target Organ
15.8.6.2.4. By Route of Administration
15.8.6.2.5. By Distribution Channel
15.8.7. Russia Market Analysis
15.8.7.1. Introduction
15.8.7.2. Market Analysis and Forecast by Market Taxonomy
15.8.7.2.1. By Therapeutics
15.8.7.2.2. By Indication
15.8.7.2.3. By Target Organ
15.8.7.2.4. By Route of Administration
15.8.7.2.5. By Distribution Channel
15.8.8. Nordic Market Analysis
15.8.8.1. Introduction
15.8.8.2. Market Analysis and Forecast by Market Taxonomy
15.8.8.2.1. By Therapeutics
15.8.8.2.2. By Indication
15.8.8.2.3. By Target Organ
15.8.8.2.4. By Route of Administration
15.8.8.2.5. By Distribution Channel
16. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By Therapeutics
16.3.3. By Indication
16.3.4. By Target Organ
16.3.5. By Route of Administration
16.3.6. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Therapeutics
16.4.3. By Indication
16.4.4. By Target Organ
16.4.5. By Route of Administration
16.4.6. By Distribution Channel
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. China Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Therapeutics
16.8.1.2.2. By Indication
16.8.1.2.3. By Target Organ
16.8.1.2.4. By Route of Administration
16.8.1.2.5. By Distribution Channel
16.8.2. Japan Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Therapeutics
16.8.2.2.2. By Indication
16.8.2.2.3. By Target Organ
16.8.2.2.4. By Route of Administration
16.8.2.2.5. By Distribution Channel
16.8.3. South Korea Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Therapeutics
16.8.3.2.2. By Indication
16.8.3.2.3. By Target Organ
16.8.3.2.4. By Route of Administration
16.8.3.2.5. By Distribution Channel
17. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. India
17.3.1.2. Indonesia
17.3.1.3. Malaysia
17.3.1.4. Thailand
17.3.1.5. Rest of South Asia
17.3.2. By Therapeutics
17.3.3. By Indication
17.3.4. By Target Organ
17.3.5. By Route of Administration
17.3.6. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Therapeutics
17.4.3. By Indication
17.4.4. By Target Organ
17.4.5. By Route of Administration
17.4.6. By Distribution Channel
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. India Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Therapeutics
17.8.1.2.2. By Indication
17.8.1.2.3. By Target Organ
17.8.1.2.4. By Route of Administration
17.8.1.2.5. By Distribution Channel
17.8.2. Indonesia Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Therapeutics
17.8.2.2.2. By Indication
17.8.2.2.3. By Target Organ
17.8.2.2.4. By Route of Administration
17.8.2.2.5. By Distribution Channel
17.8.3. Malaysia Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Therapeutics
17.8.3.2.2. By Indication
17.8.3.2.3. By Target Organ
17.8.3.2.4. By Route of Administration
17.8.3.2.5. By Distribution Channel
17.8.4. Thailand Market Analysis
17.8.4.1. Introduction
17.8.4.2. Market Analysis and Forecast by Market Taxonomy
17.8.4.2.1. By Therapeutics
17.8.4.2.2. By Indication
17.8.4.2.3. By Target Organ
17.8.4.2.4. By Route of Administration
17.8.4.2.5. By Distribution Channel
18. Oceania Market 2018 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Therapeutics
18.3.3. By Indication
18.3.4. By Target Organ
18.3.5. By Route of Administration
18.3.6. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Therapeutics
18.4.3. By Indication
18.4.4. By Target Organ
18.4.5. By Route of Administration
18.4.6. By Distribution Channel
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. Australia Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Therapeutics
18.8.1.2.2. By Indication
18.8.1.2.3. By Target Organ
18.8.1.2.4. By Route of Administration
18.8.1.2.5. By Distribution Channel
18.8.2. New Zealand Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Therapeutics
18.8.2.2.2. By Indication
18.8.2.2.3. By Target Organ
18.8.2.2.4. By Route of Administration
18.8.2.2.5. By Distribution Channel
19. Middle East and Africa (MEA) Market Analysis 2018 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Türkiye
19.3.1.3. Northern Africa
19.3.1.4. South Africa
19.3.1.5. Rest of Middle East and Africa
19.3.2. By Therapeutics
19.3.3. By Indication
19.3.4. By Target Organ
19.3.5. By Route of Administration
19.3.6. By Distribution Channel
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Therapeutics
19.4.3. By Indication
19.4.4. By Target Organ
19.4.5. By Route of Administration
19.4.6. By Distribution Channel
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
19.8.1. GCC Countries Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Therapeutics
19.8.1.2.2. By Indication
19.8.1.2.3. By Target Organ
19.8.1.2.4. By Route of Administration
19.8.1.2.5. By Distribution Channel
19.8.2. Türkiye Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Therapeutics
19.8.2.2.2. By Indication
19.8.2.2.3. By Target Organ
19.8.2.2.4. By Route of Administration
19.8.2.2.5. By Distribution Channel
19.8.3. Northern Africa Market Analysis
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Therapeutics
19.8.3.2.2. By Indication
19.8.3.2.3. By Target Organ
19.8.3.2.4. By Route of Administration
19.8.3.2.5. By Distribution Channel
19.8.4. South Africa Market Analysis
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast by Market Taxonomy
19.8.4.2.1. By Therapeutics
19.8.4.2.2. By Indication
19.8.4.2.3. By Target Organ
19.8.4.2.4. By Route of Administration
19.8.4.2.5. By Distribution Channel
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players
20.3. Market Concentration
20.4. Market Presence Analysis
20.4.1. Regional Footprint Analysis
20.4.2. Product Footprint Analysis
20.4.3. Channel Footprint Analysis
21. Competition Analysis
21.1. Competition Dashboard
21.2. Branding and Promotional Strategies, Key Players
21.3. Key Development Analysis
21.4. Competition Deep Dive
21.4.1. Pfizer Inc.
21.4.1.1. Overview
21.4.1.2. Product Portfolio
21.4.1.3. Sales Footprint
21.4.1.4. Key Developments
21.4.1.5. SWOT Analysis
21.4.1.6. Strategy Overview
21.4.1.6.1. Marketing Strategies
21.4.1.6.2. Product Strategies
21.4.1.6.3. Channel Strategies
21.4.2. Sanofi S.A
21.4.2.1. Overview
21.4.2.2. Product Portfolio
21.4.2.3. Sales Footprint
21.4.2.4. Key Developments
21.4.2.5. SWOT Analysis
21.4.2.6. Strategy Overview
21.4.2.6.1. Marketing Strategies
21.4.2.6.2. Product Strategies
21.4.2.6.3. Channel Strategies
21.4.3. Cipla Ltd
21.4.3.1. Overview
21.4.3.2. Product Portfolio
21.4.3.3. Sales Footprint
21.4.3.4. Key Developments
21.4.3.5. SWOT Analysis
21.4.3.6. Strategy Overview
21.4.3.6.1. Marketing Strategies
21.4.3.6.2. Product Strategies
21.4.3.6.3. Channel Strategies
21.4.4. Accord Healthcare Inc.
21.4.4.1. Overview
21.4.4.2. Product Portfolio
21.4.4.3. Sales Footprint
21.4.4.4. Key Developments
21.4.4.5. SWOT Analysis
21.4.4.6. Strategy Overview
21.4.4.6.1. Marketing Strategies
21.4.4.6.2. Product Strategies
21.4.4.6.3. Channel Strategies
21.4.5. Organon LLC
21.4.5.1. Overview
21.4.5.2. Product Portfolio
21.4.5.3. Sales Footprint
21.4.5.4. Key Developments
21.4.5.5. SWOT Analysis
21.4.5.6. Strategy Overview
21.4.5.6.1. Marketing Strategies
21.4.5.6.2. Product Strategies
21.4.5.6.3. Channel Strategies
21.4.6. Zydus Lifescience Ltd.
21.4.6.1. Overview
21.4.6.2. Product Portfolio
21.4.6.3. Sales Footprint
21.4.6.4. Key Developments
21.4.6.5. SWOT Analysis
21.4.6.6. Strategy Overview
21.4.6.6.1. Marketing Strategies
21.4.6.6.2. Product Strategies
21.4.6.6.3. Channel Strategies
21.4.7. Teva Pharmaceutical Industries Ltd.
21.4.7.1. Overview
21.4.7.2. Product Portfolio
21.4.7.3. Sales Footprint
21.4.7.4. Key Developments
21.4.7.5. SWOT Analysis
21.4.7.6. Strategy Overview
21.4.7.6.1. Marketing Strategies
21.4.7.6.2. Product Strategies
21.4.7.6.3. Channel Strategies
21.4.8. Novartis AG
21.4.8.1. Overview
21.4.8.2. Product Portfolio
21.4.8.3. Sales Footprint
21.4.8.4. Key Developments
21.4.8.5. SWOT Analysis
21.4.8.6. Strategy Overview
21.4.8.6.1. Marketing Strategies
21.4.8.6.2. Product Strategies
21.4.8.6.3. Channel Strategies
21.4.9. Boehringer Ingelheim Pharmaceuticals, Inc
21.4.9.1. Overview
21.4.9.2. Product Portfolio
21.4.9.3. Sales Footprint
21.4.9.4. Key Developments
21.4.9.5. SWOT Analysis
21.4.9.6. Strategy Overview
21.4.9.6.1. Marketing Strategies
21.4.9.6.2. Product Strategies
21.4.9.6.3. Channel Strategies
21.4.10. Amgen Inc
21.4.10.1. Overview
21.4.10.2. Product Portfolio
21.4.10.3. Sales Footprint
21.4.10.4. Key Developments
21.4.10.5. SWOT Analysis
21.4.10.6. Strategy Overview
21.4.10.6.1. Marketing Strategies
21.4.10.6.2. Product Strategies
21.4.10.6.3. Channel Strategies
21.4.11. F. Hoffmann-La Roche Ltd
21.4.11.1. Overview
21.4.11.2. Product Portfolio
21.4.11.3. Sales Footprint
21.4.11.4. Key Developments
21.4.11.5. SWOT Analysis
21.4.11.6. Strategy Overview
21.4.11.6.1. Marketing Strategies
21.4.11.6.2. Product Strategies
21.4.11.6.3. Channel Strategies
21.4.12. Bayer Healthcare LLC
21.4.12.1. Overview
21.4.12.2. Product Portfolio
21.4.12.3. Sales Footprint
21.4.12.4. Key Developments
21.4.12.5. SWOT Analysis
21.4.12.6. Strategy Overview
21.4.12.6.1. Marketing Strategies
21.4.12.6.2. Product Strategies
21.4.12.6.3. Channel Strategies
21.4.13. Johnson & Johnson Services Inc.
21.4.13.1. Overview
21.4.13.2. Product Portfolio
21.4.13.3. Sales Footprint
21.4.13.4. Key Developments
21.4.13.5. SWOT Analysis
21.4.13.6. Strategy Overview
21.4.13.6.1. Marketing Strategies
21.4.13.6.2. Product Strategies
21.4.13.6.3. Channel Strategies
21.4.14. Lupin Ltd
21.4.14.1. Overview
21.4.14.2. Product Portfolio
21.4.14.3. Sales Footprint
21.4.14.4. Key Developments
21.4.14.5. SWOT Analysis
21.4.14.6. Strategy Overview
21.4.14.6.1. Marketing Strategies
21.4.14.6.2. Product Strategies
21.4.14.6.3. Channel Strategies
21.4.15. GlaxoSmithKline Plc
21.4.15.1. Overview
21.4.15.2. Product Portfolio
21.4.15.3. Sales Footprint
21.4.15.4. Key Developments
21.4.15.5. SWOT Analysis
21.4.15.6. Strategy Overview
21.4.15.6.1. Marketing Strategies
21.4.15.6.2. Product Strategies
21.4.15.6.3. Channel Strategies
21.4.16. Medtronic Plc
21.4.16.1. Overview
21.4.16.2. Product Portfolio
21.4.16.3. Sales Footprint
21.4.16.4. Key Developments
21.4.16.5. SWOT Analysis
21.4.16.6. Strategy Overview
21.4.16.6.1. Marketing Strategies
21.4.16.6.2. Product Strategies
21.4.16.6.3. Channel Strategies
22. Assumptions and Acronyms Used
23. Research Methodology
Healthcare
March 2023
REP-GB-16811
298 pages
Explore Healthcare Insights
View Reports
Systemic Sclerosis Treatment Market
